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INTRODUCTION
The axillary status is the most important prognostic marker 
in patients with invasive breast cancer. Modern screening meth-
ods have increased the possibility of early detection of malig-
nant tumor in the breast. Early diagnosis of smaller carcinoma 
has gradually decreased the rate of axillary involvement. Sen-
tinel lymph node (SLN) biopsy is an accepted method for de-
fining pathologic axillary status in early cancer cases with clini-
cally negative axilla. The negative SLN is generally accepted as 
the representative of the negative axilla [1-3]. On the other hand, 
a risk for non-SLN involvement is always present despite neg-
ative SLN biopsy. Non-SLN metastasis increases the risk of ax-
illary (loco-regional) recurrence in the non-dissected axillary 
tissue. Thus, meaningful markers for predicting SLN and non-
SLN involvement in patients with early breast cancer are need-
ed. The presence of tumor emboli within the peritumoral en-
dothelial lined spaces is defined as lymphovascular invasion 
(LVI). LVI is easily established by histopathological examina-
tion. The pathological report of the presence of LVI may help 
determine whether patients with cancer are at increased risk 
for regional and systemic spread. LVI may indicate the inva-
siveness power of breast cancer as indicator of high biological 
aggressiveness [4-6]. 
In this study, we investigated the relationship between tumor 
characteristics and axillary status in patients with early breast 
cancer. The study was conducted to establish the effect of LVI 
for predicting lymphatic metastasis, especially beyond SLN.
METHODS
We analyzed 59 surgically treated patients with early breast 
cancer (invasive ductal cancer) in the years 2007 and 2008. Pa-
tients had T1 and T2 primary tumor and clinically negative 
axilla. T1 tumors were detected by physical examination and/
or by mammography and/or ultrasonography for non-palpa-
ble lesions. The diagnosis was established by core biopsy, fine 
needle aspiration or stereotactic biopsy. The SLN was identi-
fied by subareolar injection of blue dye (isosulphan blue), the 
SLN was excised via an axillary incision for pathological anal-
ysis. The mean number of removed SLNs was 1.8 (range, 1-4). 
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Purpose: The negative sentinel lymph node (SLN) biopsy avoids 
conventional axillary dissection in patients with breast cancer with 
clinically negative axilla. Despite negative SLN, there is a risk of 
leaving involved non-SLN behind in the axilla. We investigated 
the predictive power of tumor characteristics for non-SLN me-
tastasis. Methods: Lymphatic mapping with blue dye method for 
SLN biopsy and level 1-2 axillary dissections were performed to 
establish axillary status in 59 patients with T1 and T2 breast can-
cer and clinically negative axilla. Tumor’s characteristics were his-
topathologically established to assess their association with non-
SLN metastasis. Results: The axilla was malignant in 23 (39%) 
patients. The SLN alone was metastatic in 10, both SLN and non-
SLN in 9, and non-SLN alone in 4 (7%) patients. The false nega-
tive rate  for SLN biopsy was 10% in our series. The rate of posi-
tive non-SLN was found as 0% in T1a-b, 19% in T1c, and 40% in 
T2 tumors (p=0.035). Lymphovascular invasion was positive in 14 
(61%) patients with axillary metastasis (p<0.001), and in 10 (77%) 
patients with non-SLN involvement (p<0.001). Conclusion: We 
concluded that there was a small risk of involved non-SLN despite 
negative SLN. Tumor size (near or greater than 2 cm) was signifi-
cantly associated with non-SLN metastasis. Peritumoral lympho-
vascular invasion was a positive predictor of the metastatic involve-
ment in non-SLNs.
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Patients were surgically treated by total mastectomy or by wide 
local excision. Level 1 and 2 axillary dissection was then per-
formed to determine non-SLN involvement. Lymph nodes 
were identified and stained with hematoxylin and eosin (H&E) 
and examined for tumor metastasis. Tumor and peritumoral 
breast tissue were examined for LVI. The presence of tumor 
emboli within peritumoral endothelial lined spaces, stained 
with H&E is defined as positive LVI. We compared the pres-
ence of LVI and other prognostic markers with the results of 
pathological analyses regarding axillary status (SLN and non-
SLNs involvement) in order to establish the predictive value 
for prognostic markers and LVI for lymphatic metastasis. 
Statistical analysis
Variables were analyzed using Fisher’s exact test. Univariate 
and multivariate analyses were performed using SPSS
® version 
15.0 (IBM Co., Somers, USA). The p-value <0.05 was consid-
ered as significant. 
RESULTS
The mean age was 52 years (range, 29-78 years). Twenty one 
(36%) patients were premenopausal. Thirty-nine (66%) patients 
had T1 tumors. The LVI was detected in 19 (32%) patients, and 
23 (39%) patients had axillary lymphatic metastasis (Table 1). 
The SLN was metastatic in 19 patients and negative in 40. 
The SLN was the only metastatic node in 10 patients. Four pa-
tients had non-SLN metastasis despite negative SLN. There-
fore, the false negative rate (FNR) was 10% (4/40) in our series. 
The menopausal feature of the patients, and grade and hor-
mone receptor status of the primary tumors had no significant 
influence on non-SLN metastasis, but tumor size and LVI had 
an influence according to univariate and multivariate analyses 
(Table 1). 
The LVI was negative in 86% of breast cancer cases with neg-
ative axilla, and the LVI was positive in 61% (p<0.001) of cases 
with involved axilla. The presence of peritumoral LVI increased 
Table 1. Characteristic of patients and tumors and non-SLN positivity
Markers Status Patients (n=59)  
No. (%)
No. of Non-SLN (+)
(n=13)  
p-value Multivariate analysis OR  
(95% CI)
Menopausal status
 
Premenopausal
Postmenopausal
21 (36)
38 (64)
  6
  7
0.279
 
    0.565 (0.161-1.976)
 
Tumor size
 
T1 (≤2 cm)
T2 (>2 cm, ≤5 cm)
39 (66)
20 (34)
  5
  8
0.022
 
      4.533 (1.239-16.580)
 
Grade
 
 
1
2
3
17 (29)
32 (54)
10 (17)
  2
  7
  4
0.139
 
 
0.376 (0.07-1.91)
0.980 (0.28-3.37)
2.963 (0.69-12.7)
Estrogen receptor Positive
Negative
42 (71)
17 (29)
  7
  6
0.114     0.367 (0.102-1.324)
 
Progesterone receptor
 
Positive
Negative
39 (66)
20 (34)
  8
  5
0.467
 
    0.774 (0.216-2.774)
 
Axillary involvement
 
Positive
Negative
23 (39)
36 (61)
 
 
 
 
 
 
LVI
 
Positive
Negative
19 (32)
40 (68)
10
  3
<0.001
 
      3.704 (3.114-60.299)
 
SLN=sentinel lymph node; OR=odds ratio; CI=confidence interval; LVI=lymphovascular invasion.
Table 2. The relation of lymphovascular invasion and axillary status
Axillary node status
No. of  
patients 
 (n=59)
LVI
p-value No. of  
positive  
(n=19)
No. of  
negative  
(n=40)
Axillary node involvement
   Negative
   Positive
 
36
23
 
  5
14
 
31
  9
<0.001
SLN and non-SLN status
   SLN (+) alone
   SLN (+), non-SLN (+)
   SLN (-), non-SLN (+) 
 
10
  9
  4
 
  4
  6
  4
  <0.001*
LVI=lymphovascular invasion; SLN=sentinel lymph node.
*For LVI positivity in patients without non-SLN (9/46) vs. with non-SLN 
metastasis (10/13).
Table 3. The relation of tumor size with axillary status
Axillary status
No. of  
patients 
(n=59)
Tumor size
p-value T1a 
(n=4)
T1b 
(n=8)
T1c 
(n=27)
T2 
(n=20)
Axillary node involvement
   Positive
   Negative
 
23
36
 
0
4
 
2
6
 
  9
18
 
12
  8
0.019
SLN involvement
   SLN (+) alone
   SLN (+), non-SLN (+)
   SLN (-), non-SLN (+)
 
10
  9
  4
   
2
 
 
 
  4
  3
  2
 
  4
  6
  2
 0.022*
SLN=sentinel lymph node.
*For non-SLN metastasis in T1 (5/39) vs. T2 tumors (8/20).126   Gunay Gurleyik, et al.
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according to SLN and non-SLN status (Table 2). Non-SLN in-
vasion was absent (0/12) in T1a and b, and was 28% (13/47) 
in T1c and T2 tumors (p=0.035) (Table 3). Malignant cells 
have involved non-SLN in 0% of patients with T1a-b, in 19% 
(5/27) of patients with T1c and 40% (8/20) of with T2 tumors 
(p=0.022). Positive LVI was found in 77% (10/13) of patients 
with non-SLN metastasis (p<0.001) (Table 4).
DISCUSSION
Screening methods permit us to diagnose early breast can-
cer cases with clinically negative lymph nodes. The concept of 
SLN biopsy was developed in patients with early cancer in or-
der to define axillary status before formal dissection of the ax-
illa. After histopathological examination, axillary dissection 
may be avoided in patients with negative SLN biopsy [1,3,7]. 
On the other hand, a small but important risk of non-SLN in-
volvement exists despite negative SLN. These skip metastases 
increase the risk of axillary recurrence in the non-dissected tis-
sue after pathological report of negative SLN biopsy. The con-
cept of non-SLN involvement includes both skip (SLN nega-
tive, non-SLN positive) and other (SLN positive, non-SLN pos-
itive) lymph nodes metastases beyond SLNs. Although SLN 
biopsy is highly accurate for predicting axillary nodal status, it 
has been shown that the procedure has been associated with a 
several false negative results [8]. We need some indicator of 
non-SLN involvement for determining the subgroup of patients 
at risk, and prevention of loco-regional recurrence due to leav-
ing metastatic nodes behind in the non-dissected axilla when 
the SLN biopsy is negative.
Our rate (39%) of axillary involvement was slightly higher 
than that of similar series in the literature. The rate of positive 
nodes has been reported between 12% and 29% in previous 
studies of early breast cancer cases with SLN biopsy [9-12]. On 
the other hand, there are also some series with positive SLN 
biopsy rates as between 32% and 40% [13-15]. Our rate of lym-
phatic metastasis and our findings about tumor characteristics 
indicate that tumor size is an important factor for axillary in-
volvement. Relatively high rate of T2 tumors in our series in-
creased the risk of axillary metastasis. Okamoto et al. [8] re-
ported that axillary metastasis was observed in 6% of T1a and 
b and 25% of T1c tumors. 
The completion axillary dissection has been omitted in pa-
tients with negative SLN biopsy. The rate of negative SLN was 
68% (40/59) in our series. The rate of SLN free of tumor has 
been reported as 60-88% in recent series [9-15]. The FNR of 
SLN biopsy is defined as non-SLN (skip) metastases despite 
negative SLN. Our FNR of 10% (4/40) was comparable with 
those of previous series. Our higher FNR mainly resulted from 
the relatively high number of T2 cases. Some series have had   
a FNRs of 0-0.5% [9,16], and some others between 2.7% and 
17% [8,14,17-20]. The higher FNR in our T2 cases emphasizes 
the importance of tumor size. Okamoto et al. [8] have estimat-
ed the probability of FNR as 1% for T1a-b, 6% for T1c and 8% 
for T2 tumors. In some series, the risk of clinically important 
axillary recurrence has been reported as 0.5% in early cancer 
cases in whom axillary status was assessed by SLN biopsy [9, 
12,16,21]. 
The prevention of loco-regional recurrence is only possible 
by detecting false negative cases and negative SLN with skip 
(non-SLN) metastases. Carcoforo et al. [9] have reported three 
false negative cases that all three patients presented as an axil-
lary recurrence in 24 months. This result has also been con-
firmed by others [12,16,21]. How can we detect the false nega-
tive cases? Which patients have higher risk for non-SLN involve-
ment? Although the SLN biopsy was negative, the completion 
axillary lymph node dissection (ALND) must be performed 
in patients with higher risk of non-SLN involvement in order 
to eliminate the risk of leaving metastatic nodes behind in the 
axilla. In our study, the rate of non-SLN metastasis in T1c and 
in T2 tumors revealed has showed the importance of tumor 
size for lymphatic metastasis beyond SLN. The higher FNR in 
T2 cases also confirms the role of larger tumors on positive non-
SLN, despite negative SLN. Therefore, a primary tumor size 
near 2 cm or more significantly increased the risk for non-SLN 
involvement. Tan et al. [10] also reported that tumor size great-
er than 15 mm was significantly associated with SLN macro 
metastasis which had a higher risk of tumor involvement in 
non-SLN. Cao et al. [15] also pointed out the strong metastat-
ic ability of worse malignant lesions. Tumor size greater than 
Table 4. Risk factors for non-SLN metastasis
Axillary status No. of patients  
(n=59)
Tumor size
p-value* No. of LVI (+)  
(n=19)   p-value
†
T1c (n=27) T2 (n=20)
Total of non-SLN (+) 13 5 8 0.022 10 <0.001
SLN (+), non-SLN (+)   9 3 6   6
SLN (-), non-SLN (+)   4 2 2   4
SLN=sentinel lymph node; LVI=lymphvascular invasion.
*Non-SLN metastasis in T1 (5/39) vs. T2 tumors (8/20); 
†LVI (+) in patients without non-SLN (9/46) vs. with non-SLN metastasis (10/13). Tumor Characteristics for Non-SLN Metastasis 127
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2 cm was an independently significant prognostic marker for 
loco-regional recurrence, and was associated with a higher risk 
for developing lymphatic metastasis [22-25]. 
Another important marker of lymphatic spread is peritumor-
al LVI. We observed that the rate of LVI increased gradually 
according to tumor size and axillary metastasis. The diagnosis 
of early cancer cases decreased the risk of lymphatic spread in 
approximately half (10/23; 43%) of our metastatic cases with 
SLN involvement alone. The importance of micro and macro 
metastasis in SLN has been previously established [10,13,24]. 
The macrometastasis has been well documented factor for in-
creasing the risk of non-SLN involvement. Tan et al. [10] re-
ported that LVI was significantly associated with SLN macro 
metastasis. The NSABP B2 trial demonstrated that LVI increases 
the risk of lymph node involvement in 70-year-old patients with 
T1 or T2 breast cancer from 10% to 45% [26]. Our rate of pos-
itive LVI (10/13; 77%) in our patients with non-SLN metastasis 
suggested that LVI was a strong positive predictor of the non-
SLN involvement. The results of recent studies have also con-
firmed that LVI was significantly associated with lymph node 
status and non-SLN metastasis in breast cancer cases [24,27-
29]. Previous studies have recently shown that LVI and larger 
(T2) primary tumors are predictors of the risk of non-SLN me-
tastasis [25,30]. Based on ours and other findings, although SLN 
was negative, completion ALND might be considered for pa-
tients with T2 tumors and with LVI in order to eliminate the 
risk of leaving positive nodes behind and to prevent locoregion-
al recurrence. This does not mean that SLN biopsy is not suit-
able for patients with cT2N0 breast cancer. It means that sur-
geons must be more alert for non-SLN involvement in case of 
patients with larger tumor. 
One of the most important factors for patient’s survival is 
false negative cases in which non-SLN harbors malignant cells 
despite negative SLN biopsy. Despite a small number of patients, 
our LVI results in metastatic non-SLN and false negative cases 
indicated the adverse effect of LVI, which has promoted non-
SLN metastasis. It was generally accepted that negative SLN bi-
opsy cases have a better prognosis, as well as disease-free and 
overall survival. On the other hand, breast cancer cases with 
LVI have poorer prognoses among node-negative cases [22,23]. 
Node-negative patients with LVI are at higher risk for locore-
gional recurrence, relapse, disease free and overall survival [22, 
23,30]. The results of LVI and tumor size in our patients revealed 
that the presence of peritumoral LVI and larger tumor (>2 cm) 
were strong indicators of non-SLN metastasis. 
There is a small but important risk of false negative SLN bi-
opsy when non-SLN is involved with malignant cells despite 
negative SLN. Greater tumor size and positive LVI were adverse 
markers for axillary metastasis. Tumor size (>2 cm) was signif-
icantly associated with non-SLN metastasis. Peritumoral LVI 
was a positive predictor of the metastatic involvement of non-
SLN. Despite negative SLN, completion ALND may be consid-
ered in patients with larger tumor and positive LVI in order to 
avoid leaving metastatic non-SLNs behind in the axilla.
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